December, 2024, in the United States, Eutropics and the Keck School of Medicine of the University of Southern California (USC) entered a research collaboration with the to evaluate its PRIMAB™ Dx diagnostic platform in Acute Myeloid Leukemia (AML). The study aims to assess how PRIMAB’s functional biomarker approach can help predict patient response to targeted and combination therapies in AML, a disease with considerable heterogeneity and unmet clinical need. The study will be led by Dr. Kevin Kelly, Professor of Clinical Medicine and an expert in hematologic malignancies at Keck/USC. Dr. Kelly’s research focuses on improving clinical outcomes for patients with AML through precision-based treatment strategies, making this collaboration a strong alignment with Eutropics’ mission to translate functional diagnostics into real-world clinical impact “This initiative expands the clinical reach of PRIMAB Dx into AML, where functional measures of treatment susceptibility may significantly enhance therapeutic decision-making,” said Michael Cardone. “We’re honored to collaborate with Dr. Kelly and his team as we work to bring more predictive, actionable tools to oncologists and their patients.” This partnership continues Eutropics’ strategy of advancing the PRIMAB platform across a range of hematologic cancers through leading academic collaborations.
